Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington, N. George Mikhaeel, Lale Kostakoğlu, et al.
Journal of Clinical Oncology (2014) Vol. 32, Iss. 27, pp. 3048-3058
Open Access | Times Cited: 1474

Showing 1-25 of 1474 citing articles:

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson, Richard I. Fisher, Sally F. Barrington, et al.
Journal of Clinical Oncology (2014) Vol. 32, Iss. 27, pp. 3059-3067
Open Access | Times Cited: 4574
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Ronald Boellaard, Roberto C. Delgado Bolton, Wim J.G. Oyen, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2014) Vol. 42, Iss. 2, pp. 328-354
Open Access | Times Cited: 2714
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar, Bruno Paiva, Kenneth C. Anderson, et al.
The Lancet Oncology (2016) Vol. 17, Iss. 8, pp. e328-e346
Closed Access | Times Cited: 2390
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, et al.
Journal of the National Comprehensive Cancer Network (2018) Vol. 16, Iss. 3, pp. 310-320
Open Access | Times Cited: 1597
Non-Hodgkin lymphoma
Jamés O. Armitage, Randy D. Gascoyne, Matthew A. Lunning, et al.
The Lancet (2017) Vol. 390, Iss. 10091, pp. 298-310
Closed Access | Times Cited: 1074
Imaging biomarker roadmap for cancer studies
James P.B. O’Connor, Eric O. Aboagye, Judith E. Adams, et al.
Nature Reviews Clinical Oncology (2016) Vol. 14, Iss. 3, pp. 169-186
Open Access | Times Cited: 940
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hervé Tilly, María Gomes da Silva, Umberto Vitolo, et al.
Annals of Oncology (2015) Vol. 26, pp. v116-v125
Open Access | Times Cited: 800
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Peter Johnson, Massimo Federico, Amy A. Kirkwood, et al.
New England Journal of Medicine (2016) Vol. 374, Iss. 25, pp. 2419-2429
Open Access | Times Cited: 724
Diffuse Large B-Cell Lymphoma
Laurie H. Sehn, Gilles Salles
New England Journal of Medicine (2021) Vol. 384, Iss. 9, pp. 842-858
Open Access | Times Cited: 673
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
Laurie H. Sehn, Randy D. Gascoyne
Blood (2014) Vol. 125, Iss. 1, pp. 22-32
Closed Access | Times Cited: 506
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Branimir I. Šikić, Nehal J. Lakhani, Amita Patnaik, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 12, pp. 946-953
Open Access | Times Cited: 481
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dennis A. Eichenauer, Andreas Engert, M. André, et al.
Annals of Oncology (2014) Vol. 25, pp. iii70-iii75
Open Access | Times Cited: 455
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase
Yok‐Lam Kwong, Thomas S. Y. Chan, Daryl Tan, et al.
Blood (2017) Vol. 129, Iss. 17, pp. 2437-2442
Open Access | Times Cited: 442
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
Bruce D. Cheson, Stephen M. Ansell, Lawrence H. Schwartz, et al.
Blood (2016) Vol. 128, Iss. 21, pp. 2489-2496
Open Access | Times Cited: 436
Hodgkin lymphoma: A review and update on recent progress
Satish Shanbhag, Richard F. Ambinder
CA A Cancer Journal for Clinicians (2017) Vol. 68, Iss. 2, pp. 116-132
Open Access | Times Cited: 428
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam, Mary Ann Anderson, Christiane Pott, et al.
New England Journal of Medicine (2018) Vol. 378, Iss. 13, pp. 1211-1223
Open Access | Times Cited: 379
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dennis A. Eichenauer, Berthe M.P. Aleman, M. André, et al.
Annals of Oncology (2018) Vol. 29, pp. iv19-iv29
Open Access | Times Cited: 360
Non-Hodgkin Lymphoma: Diagnosis and Treatment
Stephen M. Ansell, Jamés O. Armitage
Mayo Clinic Proceedings (2005) Vol. 80, Iss. 8, pp. 1087-1097
Closed Access | Times Cited: 341
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines
Jan Styczyński, Walter J. F. M. van der Velden, Christopher P. Fox, et al.
Haematologica (2016) Vol. 101, Iss. 7, pp. 803-811
Open Access | Times Cited: 331
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
Anas Younes, Patrick Hilden, Bertrand Coiffier, et al.
Annals of Oncology (2017) Vol. 28, Iss. 7, pp. 1436-1447
Open Access | Times Cited: 312
RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group
Lawrence H. Schwartz, Lesley Seymour, Saskia Litière, et al.
European Journal of Cancer (2016) Vol. 62, pp. 138-145
Open Access | Times Cited: 285
Positron Emission Tomography (PET) in Oncology
Andrea Gallamini, C. Zwarthoed, Anna Borra
Cancers (2014) Vol. 6, Iss. 4, pp. 1821-1889
Open Access | Times Cited: 280
Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies
Michel Meignan, Anne‐Ségolène Cottereau, Annibale Versari, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 30, pp. 3618-3626
Closed Access | Times Cited: 278
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816
Oliver W. Press, Hongli Li, Heiko Schöder, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 17, pp. 2020-2027
Open Access | Times Cited: 255
Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL
N. George Mikhaeel, Daniel Smith, Joel Dunn, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2016) Vol. 43, Iss. 7, pp. 1209-1219
Open Access | Times Cited: 244
Page 1 - Next Page

Scroll to top